George Zhang Selected Research

edoxaban

1/2020	Clinical implications of incidental venous thromboembolism in cancer patients.
8/2018	Clinical Impact of Bleeding in Cancer-Associated Venous Thromboembolism: Results from the Hokusai VTE Cancer Study.
2/2018	Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism.
1/2018	An Open-Label Crossover Study of the Pharmacokinetics of the 60-mg Edoxaban Tablet Crushed and Administered Either by a Nasogastric Tube or in Apple Puree in Healthy Adults.
1/2018	Impact of age, comorbidity, and polypharmacy on the efficacy and safety of edoxaban for the treatment of venous thromboembolism: An analysis of the randomized, double-blind Hokusai-VTE trial.
11/2017	Genetics and clinical response to warfarin and edoxaban in patients with venous thromboembolism.
1/2017	Prediction of major and clinically relevant bleeding in patients with VTE treated with edoxaban or vitamin K antagonists.
9/2016	Dose reduction of edoxaban preserves efficacy and safety for the treatment of venous thromboembolism. An analysis of the randomised, double-blind HOKUSAI VTE trial.
9/2016	Recurrent venous thromboembolism in patients with pulmonary embolism and right ventricular dysfunction: a post-hoc analysis of the Hokusai-VTE study.
8/2016	Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

George Zhang Research Topics

Disease

12	Venous Thromboembolism 04/2019 - 07/2012
9	Neoplasms (Cancer) 10/2022 - 08/2016
8	Hemorrhage 08/2018 - 08/2016
4	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 02/2023 - 12/2021
3	Infections 11/2022 - 01/2019
3	Neuroendocrine Tumors (Neuroendocrine Tumor) 01/2021 - 01/2019
3	Pulmonary Embolism 01/2018 - 08/2016
2	Adenocarcinoma 10/2023 - 01/2021
2	Neoplasm Metastasis (Metastasis) 10/2022 - 01/2019
2	Primitive Neuroectodermal Tumors (PNET) 01/2021 - 01/2019
2	Clostridium Infections 12/2018 - 01/2018
2	Body Weight (Weight, Body) 02/2018 - 09/2016
2	Atrial Fibrillation 01/2018 - 10/2013
2	Stroke (Strokes) 01/2018 - 10/2013
2	Embolism (Embolus) 01/2018 - 10/2013
1	Disease Progression 05/2024
1	COVID-19 05/2024
1	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2023
1	Chronic Hepatitis B 11/2022
1	Lung Neoplasms (Lung Cancer) 10/2022
1	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2022
1	Thrombocytosis (Thrombocythemia) 01/2022
1	Anemia 12/2021
1	Pancreatic Neoplasms (Pancreatic Cancer) 01/2021
1	Cystic Fibrosis (Mucoviscidosis) 01/2020
1	Inflammation (Inflammations) 01/2020
1	Multiple Endocrine Neoplasia Type 1 01/2019
1	Gastrointestinal Neoplasms (Gastrointestinal Cancer) 08/2018
1	Angioedema 08/2017
1	Hypertension (High Blood Pressure) 01/2017
1	Right Ventricular Dysfunction 09/2016
1	Venous Thrombosis (Deep-Vein Thrombosis) 08/2016
1	Bladder Exstrophy (Exstrophy, Bladder) 05/2005
1	Prostatic Neoplasms (Prostate Cancer) 03/2002
1	Hyperinsulinism (Hyperinsulinemia) 03/2002
1	Hirsutism 03/2002
1	Polycystic Ovary Syndrome (Syndrome, Stein-Leventhal) 03/2002

Drug/Important Bio-Agent (IBA)

12	edoxabanIBA 01/2020 - 07/2012
7	Warfarin (Coumadin)FDA LinkGeneric 04/2019 - 08/2016
5	AnticoagulantsIBA 01/2020 - 08/2016
3	luspaterceptIBA 11/2022 - 12/2021
3	Dalteparin (Dalteparin Sodium)FDA Link 01/2020 - 02/2018
3	Heparin (Liquaemin)FDA LinkGeneric 01/2018 - 09/2016
3	Factor Xa InhibitorsIBA 01/2018 - 10/2013
2	Hyaluronic Acid (Hyaluronan)IBA 01/2021 - 01/2019
2	Proteins (Proteins, Gene)FDA Link 12/2020 - 01/2019
2	Insulin (Novolin)FDA Link 01/2019 - 03/2002
2	RNA (Ribonucleic Acid)IBA 01/2019 - 05/2005
2	DS-2969bIBA 12/2018 - 01/2018
2	Low-Molecular-Weight Heparin (Heparin, Low Molecular Weight)IBA 02/2018 - 08/2016
2	pro-brain natriuretic peptide (1-76)IBA 01/2018 - 09/2016
2	Member 1 Subfamily B ATP Binding Cassette TransporterIBA 09/2016 - 08/2016
2	CreatinineIBA 09/2016 - 08/2016
1	TabletsIBA 05/2024
1	Ritonavir (Norvir)FDA Link 05/2024
1	130-nm albumin-bound paclitaxelIBA 10/2023
1	Gemcitabine FDA Link 10/2023
1	Azacitidine (5 Azacytidine)FDA Link 01/2023
1	AntigensIBA 11/2022
1	GST-HG131IBA 11/2022
1	Carbon MonoxideIBA 10/2022
1	Fibronectins (Fibronectin)IBA 10/2022
1	Therapeutic UsesIBA 10/2022
1	osimertinibIBA 01/2022
1	Anaphase-Promoting Complex-CyclosomeIBA 01/2021
1	CytokinesIBA 01/2020
1	Cannabinoid Receptors (Cannabinoid Receptor)IBA 01/2020
1	lenabasum (ajulemic acid)IBA 01/2020
1	hyaluronan-mediated motility receptorIBA 01/2019
1	OilsIBA 01/2019
1	oleocanthalIBA 01/2019
1	DNA (Deoxyribonucleic Acid)IBA 01/2019
1	Messenger RNA (mRNA)IBA 01/2019
1	Olive OilIBA 01/2019
1	AcidsIBA 01/2019
1	DNA (Cytosine-5-)-Methyltransferase 1IBA 01/2019
1	Protein Isoforms (Isoforms)IBA 01/2019
1	Cytochrome P-450 CYP2C9IBA 11/2017
1	Histamine Antagonists (Antihistamines)IBA 08/2017
1	Adrenal Cortex Hormones (Corticosteroids)IBA 08/2017
1	Vitamin K FDA Link 01/2017
1	Brain Natriuretic Peptide (Natrecor)FDA Link 09/2016
1	Blood Coagulation Factors (Coagulation Factor)IBA 08/2016
1	Verapamil (Calan)FDA LinkGeneric 08/2016
1	PlacebosIBA 08/2016
1	Quinidine (Chinidin)FDA LinkGeneric 08/2016
1	Enoxaparin (Lovenox)FDA LinkGeneric 07/2012
1	Insulin-Like Growth Factor II (Somatomedin A)IBA 03/2002
1	Insulin-Like PeptidesIBA 03/2002
1	Insulin-Like Growth Factor I (IGF-1)IBA 03/2002
1	AndrogensIBA 03/2002
1	Troglitazone (Rezulin)FDA Link 03/2002
1	PPAR-gamma AgonistsIBA 03/2002

Therapy/Procedure

5	Therapeutics 10/2022 - 01/2017
3	Duration of Therapy 08/2018 - 01/2017
2	Erythrocyte Transfusion 02/2023 - 12/2021
1	Drug Therapy (Chemotherapy) 01/2023
1	Wearable Electronic Devices 01/2019
1	Polypharmacy 01/2018
1	Drug Tapering 09/2016